Oncimmune Holdings PLC Annual Report and Accounts and AGM Notification (4505V)
03 November 2017 - 6:00PM
UK Regulatory
TIDMONC
RNS Number : 4505V
Oncimmune Holdings PLC
03 November 2017
3 November 2017
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Annual Report and Accounts and AGM Notification
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer
detection company developing and commercialising its proprietary
EarlyCDT(R) platform technology, today gives notice that copies of
the Annual Report and Accounts for the year ended 31 May 2017 and
the Notice of Annual General Meeting ("AGM") have been sent to
shareholders. These documents are available to view on the
"Investors" section of the Company's website at
http://oncimmune.com/. Oncimmune announced results for the year
ended 31 May 2017 on 20 October 2017.
Further copies of the Annual Report will be available from the
Company Secretary, Oncimmune, Clinical Sciences Building,
Nottingham City Hospital, Hucknall Road, Nottingham
NG5 1PB.
Oncimmune also announces that its Annual General Meeting will be
held on 29 November 2017. The meeting will be held at Peachey &
Co LLP, 95 Aldwych, London, WC2B 4JF, commencing at 9.30 am.
-Ends-
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Giles Balleny, Hugh Kingsmill Moore
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
About Oncimmune
Oncimmune is a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT(R) platform
technology. Oncimmune has pioneered the development of autoantibody
tests that can detect cancer up to four years earlier than other
methods and can be applied to a very wide range of solid tumour
types. The Company's first product, EarlyCDT(R)-Lung, was launched
in 2012, as a CLIA test in the USA and since then over 150,000
commercial tests have been sold. EarlyCDT(R)-Lung is available
through physicians in the US and also privately in the UK and other
regions. EarlyCDT(R)-Lung is being used in the largest ever
randomised trial for the early detection of lung cancer using
biomarkers, the National Health Service (NHS) Scotland ECLS study
of 12,210 high-risk smokers. EarlyCDT(R) tests for liver and
ovarian cancer are in development.
Oncimmune is headquartered in Nottingham, United Kingdom with
testing facilities in the US and joined AIM in May 2016 under the
ticker ONC.L. For more information, visit www.oncimmune.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKMMGMVZLGNZM
(END) Dow Jones Newswires
November 03, 2017 03:00 ET (07:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024
